Travere Therapeutics, Inc. (NASDAQ:TVTX) Forecasted to Earn FY2026 Earnings of $2.81 Per Share

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Equities researchers at Wedbush upped their FY2026 earnings estimates for shares of Travere Therapeutics in a report issued on Wednesday, October 9th. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of $2.81 for the year, up from their previous estimate of $2.28. Wedbush has a “Outperform” rating and a $25.00 price target on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.95) per share. Wedbush also issued estimates for Travere Therapeutics’ FY2027 earnings at $3.83 EPS and FY2028 earnings at $3.92 EPS.

Other equities analysts also recently issued reports about the stock. JPMorgan Chase & Co. lifted their price objective on shares of Travere Therapeutics from $20.00 to $23.00 and gave the stock an “overweight” rating in a report on Friday, September 13th. Citigroup cut their price objective on shares of Travere Therapeutics from $23.00 to $19.00 and set a “buy” rating on the stock in a report on Friday, September 27th. Leerink Partners reaffirmed an “outperform” rating and set a $20.00 price objective on shares of Travere Therapeutics in a report on Tuesday. Barclays lifted their price objective on shares of Travere Therapeutics from $14.00 to $18.00 and gave the stock an “overweight” rating in a report on Tuesday, October 1st. Finally, Canaccord Genuity Group lowered their target price on Travere Therapeutics from $23.00 to $22.00 and set a “buy” rating on the stock in a research note on Monday, September 30th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, Travere Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $19.75.

Travere Therapeutics Price Performance

TVTX opened at $16.41 on Friday. The company has a debt-to-equity ratio of 24.96, a current ratio of 3.04 and a quick ratio of 2.99. The company has a market capitalization of $1.26 billion, a price-to-earnings ratio of -8.73 and a beta of 0.73. The firm’s fifty day moving average price is $11.78 and its two-hundred day moving average price is $8.96. Travere Therapeutics has a 1 year low of $5.12 and a 1 year high of $18.60.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.03). The firm had revenue of $54.12 million for the quarter, compared to analysts’ expectations of $49.50 million. Travere Therapeutics had a negative return on equity of 269.18% and a negative net margin of 82.14%.

Hedge Funds Weigh In On Travere Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in TVTX. EntryPoint Capital LLC bought a new position in Travere Therapeutics in the first quarter worth $32,000. CWM LLC raised its holdings in Travere Therapeutics by 158.5% in the third quarter. CWM LLC now owns 4,999 shares of the company’s stock worth $70,000 after purchasing an additional 3,065 shares in the last quarter. DRW Securities LLC bought a new position in Travere Therapeutics in the second quarter worth $95,000. Forefront Analytics LLC raised its holdings in Travere Therapeutics by 10.2% in the second quarter. Forefront Analytics LLC now owns 13,317 shares of the company’s stock worth $109,000 after purchasing an additional 1,237 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Travere Therapeutics by 68.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 14,652 shares of the company’s stock worth $113,000 after purchasing an additional 5,962 shares in the last quarter.

Insiders Place Their Bets

In other Travere Therapeutics news, SVP William E. Rote sold 4,387 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $11.52, for a total value of $50,538.24. Following the completion of the sale, the senior vice president now owns 84,455 shares of the company’s stock, valued at $972,921.60. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Jula Inrig sold 2,191 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $11.52, for a total transaction of $25,240.32. Following the completion of the transaction, the insider now owns 62,633 shares in the company, valued at $721,532.16. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP William E. Rote sold 4,387 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $11.52, for a total value of $50,538.24. Following the transaction, the senior vice president now owns 84,455 shares of the company’s stock, valued at approximately $972,921.60. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 110,707 shares of company stock valued at $1,504,312 over the last quarter. 3.75% of the stock is owned by corporate insiders.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.